Sanofi Licenses OTC Tamiflu From Roche To Attempt First US Flu Treatment Switch
Executive Summary
Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.
You may also be interested in...
Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed
After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.
Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug
Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.
Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines
Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.